Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity

Recruiting Observational Study
Binge Eating Disorder Associated With Obesity Binge Eating Disorder Eating Disorder Binge Eating Disorders GLP-1 CBT Obesity &Amp; Overweight
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 65
Sex
Any
Study type
Observational
Participants needed
80 (estimated)
Sponsor
Haukeland University Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This study is a clinical, longitudinal, non-randomized, prospective observational study that seeks to compare the treatment effects and safety of using GLP-1 analogues versus not using appetite suppressants during a lifestyle treatment program that includes individual consultations every fourth month and 10 weeks of CBT-E group therapy in patients with both obesity and BED. The primary objective …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria 1. Severe obesity defined as BMI \>40 kg/m2 or 35 kg/m2 with obesity-related comorbidities: coronary artery disease, heart failure, hypertension, atrial fibrillation, cerebral stroke, venous thromboembolism, obstructive sleep apnea, obesity hypoventilation syndrome, type 2 diabet…
Contacts

Malin M Kleppe, PhD candidate

+47 99357771

malin.mandelid.kleppe@helse-bergen.no

CONTACT